Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Dr. Richard Béliveau, Ph.D.

Advisor

Richard Béliveau Photo

Richard Béliveau, Ph.D. in Biochemistry, is Scientific Director of the Chair in Prevention and Treatment of Cancer of the Université du Québec à Montréal.

He was Professor of Surgery and Physiology at Université de Montréal and held the Chair of Neurosurgery of the CHUM. He is an associate researcher at the Cancer Prevention Center in the Department of Oncology at McGill University and member of the Experimental Cancer Therapy Group at the Jewish General Hospital of Montreal. He is full Professor of Biochemistry at Université du Québec à Montréal and member of the Coalition Priorité Cancer au Québec. He is the founder of Angiochem and Katana Biopharma, two biotech companies that develop new drugs targeting brain disorders and various types of cancer.

He has published more than 250 articles in world-class scientific and medical journals. He also authored several best-selling books that have been translated into 28 languages across 37 countries, including “Foods that Fight Cancer”, “Cooking with Foods that Fight Cancer”, “Eating Well, Living Well”, “Death: the Scientific Facts”, “Samurai”, and “Preventing Cancer”. He wrote more than 550 medical research columns in the Journal de Montréal. He was awarded the Public’s Choice Prize at the Salon du Livre de Montréal, he was named Person of the Year by L’Actualité magazine and Personality of Quebec province by Au Québec newspaper. He was also named Emeritus alumnus of the Collège de Trois-Rivières, Université du Québec and Université Laval. He is Professor Emeritus of Biochemistry.

    Headquarters

    Theratechnologies inc.
    2015 Peel Street, 11th Floor
    Montréal, Québec
    Canada H3A 1T8
    Phone: 514 336-7800
    Fax: 514 331-9691

    European Headquarters

    Theratechnologies Europe Limited
    2 Hume Street, 4th floor
    Dublin 2
    Ireland D02 DV24
    Phone: +353 1 215 0650
    europe@theratech.com

    Investor Relations

    Elif McDonald
    Senior Director, Investor Relations
    Phone: +1-438-315-8563
    ir@theratech.com

    US Headquarters

    Theratechnologies U.S., Inc.
    101 Hudson Street
    21st Floor
    Jersey City, New Jersey 07302

    Main Nav

    • Home
    • About
    • Medicines & Pipeline
    • Investors
    • Corporate Responsibility
    • Careers
    • Contact Us
    ©2023 - Theratechnologies Inc.

    Legal Nav

    • Terms of Use
    • Privacy

    Search

    Theratechnologies